公开(公告)号：US20080214544A1

公开(公告)日：2008-09-04

申请号：US12004284

申请日：2007-12-19

Applicant: Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Ingrid M. Fellows ,  Jean-Christophe Harmange ,  Tae-Seong Kim ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman

Inventor： Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Ingrid M. Fellows ,  Jean-Christophe Harmange ,  Tae-Seong Kim ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman

IPC: A61K31/5377 ,  C07D403/12 ,  C07D413/14 ,  A61K31/496 ,  A61P29/00 ,  A61P19/02 ,  A61P35/00 ,  A61P3/10 ,  C07D401/14 ,  A61K31/513

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as c-met mediated diseases and/or HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 选择的化合物对于预防和治疗诸如c-met介导的疾病和/或HGF介导的疾病的疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US20080200464A1

公开(公告)日：2008-08-21

申请号：US12004153

申请日：2007-12-19

Applicant: Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Julie Germain ,  Jean-Christophe Harmange ,  Tae-Seong Kim ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Elizabeth Rainbeau ,  Ning Xi ,  Shimin Xu

Inventor： Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Julie Germain ,  Jean-Christophe Harmange ,  Tae-Seong Kim ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Elizabeth Rainbeau ,  Ning Xi ,  Shimin Xu

IPC: A61K31/5377 ,  C07D413/14 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/506 ,  C07D401/12 ,  A61P35/00

CPC classification number: C07D213/82 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US06187777B1

公开(公告)日：2001-02-13

申请号：US09246775

申请日：1999-02-04

Applicant: Mark Henry Norman ,  Clarence R. Hurt ,  Ning Chen ,  Christopher H. Fotsch ,  Nianhe Han ,  Tracy J. Jenkins ,  Longbin Liu ,  Ofir A. Moreno

Inventor： Mark Henry Norman ,  Clarence R. Hurt ,  Ning Chen ,  Christopher H. Fotsch ,  Nianhe Han ,  Tracy J. Jenkins ,  Longbin Liu ,  Ofir A. Moreno

IPC: A61K31519

CPC classification number: C07D491/04 ,  A61K31/437 ,  A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

Abstract: There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Abstract translation: 提供了在调节进食行为，肥胖症，糖尿病，癌症（肿瘤），炎症性疾病，抑郁症，应激相关疾病，阿尔茨海默氏病和其他疾病状况中使用的化合物，组合物和方法。

公开(公告)号：US11028398B2

公开(公告)日：2021-06-08

申请号：US13275205

申请日：2011-10-17

Applicant: Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

Inventor： Haitao Wang ,  Yong Du ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

IPC: C07K1/00 ,  A61K45/00 ,  A61K39/00 ,  C12N15/62 ,  A61K47/68 ,  C07K16/00

Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.

公开(公告)号：US20130189226A1

公开(公告)日：2013-07-25

申请号：US13841679

申请日：2013-03-15

Applicant: Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Ling WANG ,  Yong DU ,  Longbin LIU ,  Jing XU ,  Rui ZHANG

Inventor： Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Ling WANG ,  Yong DU ,  Longbin LIU ,  Jing XU ,  Rui ZHANG

IPC: C07K14/56

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inteferon like alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，描述了与天然存在的人类干扰素如α2b（HuIFN-α2b）相比，通过基因改组技术产生的重组蛋白具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US20120225854A1

公开(公告)日：2012-09-06

申请号：US13215914

申请日：2011-08-23

Applicant: Kate Ashton ,  Michael David Bartberger ,  Yunxin Bo ,  Marian C. Bryan ,  Michael Croghan ,  Christopher Harold Fotsch ,  Clarence Henderson Hale ,  Roxanne Kay Kunz ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Lewis Dale Pennington ,  Steve Fong Poon ,  Markian Myroslaw Stec ,  David Joseph St. Jean, JR. ,  Nuria A. Tamayo ,  Christopher Michael Tegley ,  Kevin Chao Yang

Inventor： Kate Ashton ,  Michael David Bartberger ,  Yunxin Bo ,  Marian C. Bryan ,  Michael Croghan ,  Christopher Harold Fotsch ,  Clarence Henderson Hale ,  Roxanne Kay Kunz ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Lewis Dale Pennington ,  Steve Fong Poon ,  Markian Myroslaw Stec ,  David Joseph St. Jean, JR. ,  Nuria A. Tamayo ,  Christopher Michael Tegley ,  Kevin Chao Yang

IPC: A61K31/496 ,  A61P27/02 ,  A61P13/12 ,  A61P25/00 ,  A61P27/12 ,  A61P27/06 ,  A61P3/04 ,  A61P15/00 ,  C07D409/12 ,  C07D295/26 ,  A61K31/495 ,  C07D403/12 ,  C07D401/12 ,  C07D409/14 ,  A61K31/506 ,  C07D213/46 ,  A61K31/4418 ,  C07C317/22 ,  A61K31/10 ,  C07D405/12 ,  C07D417/10 ,  C07D413/14 ,  A61K31/5377 ,  C07D498/08 ,  A61K31/5386 ,  C07D491/107 ,  C07D417/14 ,  A61K31/541 ,  C07D401/14 ,  C07D491/048 ,  C07D471/08 ,  C07D211/54 ,  A61K31/451 ,  A61K31/501 ,  C07D487/04 ,  A61K31/4985 ,  C07D403/04 ,  C07D491/08 ,  A61P3/10

CPC classification number: C07D333/34 ,  C07C317/22 ,  C07D213/30 ,  C07D213/32 ,  C07D213/71 ,  C07D213/72 ,  C07D213/74 ,  C07D231/18 ,  C07D239/42 ,  C07D241/04 ,  C07D277/36 ,  C07D285/135 ,  C07D295/26 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D498/08

Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Abstract translation: 本发明涉及与葡萄糖激酶调节蛋白相互作用的式I化合物或其药学上可接受的盐。 此外，本发明涉及治疗2型糖尿病的方法，以及其中使用所述化合物或其药学上可接受的盐涉及葡萄糖激酶调节蛋白的其它疾病和/或病症，以及含有所述化合物或其药学上可接受的盐的药物组合物 其中。

公开(公告)号：US20120148531A1

公开(公告)日：2012-06-14

申请号：US13309488

申请日：2011-12-01

Applicant: Brian K. ALBRECHT ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

Inventor： Brian K. ALBRECHT ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

IPC: A61K31/5025 ,  A61K31/5377 ,  A61K38/21 ,  A61P35/00 ,  A61P35/04 ,  C07D487/04 ,  A61K31/538

CPC classification number: A61K31/538 ,  A61K31/437 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  C07D403/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D493/04 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US08088794B2

公开(公告)日：2012-01-03

申请号：US12945575

申请日：2010-11-12

Applicant: Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessandro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

Inventor： Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessandro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

IPC: A61K31/47 ,  C07D453/02

CPC classification number: C07D413/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US07867482B2

公开(公告)日：2011-01-11

申请号：US12555759

申请日：2009-09-08

Applicant: Haitao Wang ,  Chungsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

Inventor： Haitao Wang ,  Chungsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

IPC: A61K38/21 ,  C07K14/00 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

公开(公告)号：US20100129904A1

公开(公告)日：2010-05-27

申请号：US12555762

申请日：2009-09-08

Applicant: Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

Inventor： Haitao WANG ,  Chunsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

IPC: C12N5/10 ,  C07H21/04 ,  C12N15/63 ,  C12N1/21

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.